Sorry, you need to enable JavaScript to visit this website.
Skip to main content

Search

Infectious Diseases & Vaccines: Leadership

Infectious Diseases & Vaccines: Leaders

 

Infectious Diseases & Vaccines

Infectious Diseases & Vaccines

The structure of HIV
The structure of HIV

JAMES MERSON, PH.D.

GLOBAL THERAPEUTIC HEAD
INFECTIOUS DISEASES

James Merson, Ph.D., is the Global Therapeutic Area Head for Infectious Diseases at Janssen Research & Development, L.L.C. He leads a global team focused on continuously creating and progressing transformational medicines to help fight infectious diseases including influenza, respiratory syncytial virus (RSV), HIV and hepatitis B.

James holds more than 25 years of R&D experience in antivirals, vaccines (prophylactic and therapeutic) and immuno-oncology. Previously at Pfizer, Inc., he held a succession of leadership positions including Chief Scientific Officer of the Vaccine Immunotherapeutics Research Unit, co-leader of Infectious Diseases and Head of their Antiviral Therapeutic Area. Throughout his tenure, James led the development of a series antiviral molecules for the treatment of HIV (CCR5 antagonist) and hepatitis C. He also realized the potential of antibacterial macromolecules and the clinical evaluation of novel broad-spectrum antibiotics.

James is committed to exploring new avenues of research in the fight against infectious diseases. In addition to his antiviral expertise, his research has been focused on immuno-oncology and the combination of vaccines, oncolytic viruses and immunomodulators to treat chronic diseases which include various types of cancers.

He holds a Ph.D. in microbiology and immunology from Baylor College of Medicine, Houston, Texas and a B.A. in biology from Bellarmine College, Louisville, Kentucky. He is a member of the New York Academy of Sciences, the British Society of Immunology and the International Society of Vaccines, and has served on several scientific advisory and company boards.

James Merson, Ph.D.

Global Therapeutic Head
Infectious Diseases

SAMUELE BUTERA

GLOBAL COMMERCIAL STRATEGY LEADER
INFECTIOUS DISEASES AND VACCINES
GLOBAL COMMERCIAL STRATEGY ORGANIZATION

Samuele Butera is the Global Commercial Strategy Leader for Infectious Diseases and Vaccines. He leads our efforts to build and maximize the value of the infectious diseases portfolio and pipeline in areas of high unmet need such as HIV, hepatitis B, respiratory syncytial virus (RSV) and influenza.

With a proven track record in delivering global healthcare innovation and business leadership, Samuele’s goal is to bring transformational solutions to patients, providers and healthcare systems around the world.

Prior to joining Janssen, Samuele spent 13 years at Novartis, where he was most recently the Global Cell & Gene Therapies Business Leader in Oncology. In this role he was responsible for leading and overseeing all of Novartis’ activities to ensure the successful global launch of cell and gene therapies, which included the first CAR-T therapy for children and young adults with B-cell acute lymphoblastic leukemia. He also oversaw the market preparations for the launch of the first U.S. biosimilar while leading Sandoz Biopharmaceuticals North America.

Samuele was formerly a consultant at McKinsey & Company, where he advised clients on corporate strategy, mergers and acquisitions, alliances, operational effectiveness, and organizational redesign. He has also worked in financial markets with Goldman Sachs, and on international economic development initiatives with the United Nations.

Samuele earned a Bachelor of Science in International Economics from Bocconi University in Milan, Italy, and a Master’s degree in Public Policy from Harvard University in Boston, Massachusetts.

Samuele Butera

Global Commercial Strategy Leader
Infectious Diseases and Vaccines
Global Commercial Strategy Organization

JOHAN VAN HOOF, M.D.

GLOBAL THERAPEUTIC AREA HEAD
IDV, VACCINES
MANAGING DIRECTOR
JANSSEN VACCINES AND PREVENTION, B.V.

Johan Van Hoof, M.D. received his medical degree (cum laude) from the University of Antwerp, Belgium, in the Department of Anatomy and Embryology at Rijksuniversitair Centrum Antwerpen, Belgium. He studied business management at Krauthammer International School and the International Executive Programme INSEAD, Fontainebleau, France.

Johan joined the Johnson & Johnson Family of Companies in April 2005 as Vice President, Data Management and Early Clinical Development. Following roles as Chief Operating Officer (COO) of Johnson & Johnson Pharmaceutical Research, LLC, and Head of the Global Development Organization, he was appointed Global Therapeutic Area Head for Infectious Diseases & Vaccines in 2010. Since 2011 he has been overseeing research & development at Janssen Vaccines as Managing Director.

Before joining the Johnson & Johnson Family of Companies, Johan acquired more than 20 years of experience in the vaccine industry, having worked with Pasteur Mérieux Connaught, Chiron Vaccines and GlaxoSmithKline (GSK) Biologicals. During this period, he held leadership roles with increasing responsibilities, including Head New Product Development at GSK Biologicals. Johan was actively involved in the development and licensing of a new generation of childhood and adult vaccines in disease areas such as pertussis (pediatric combined vaccines), meningitis, rotaviral diarrhea, hepatitis, flu and HPV.

Johan Van Hoof, M.D.

Global Therapeutic Area Head
IDV, Vaccines
Managing Director
Janssen Vaccines and Prevention, B.V.